A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (AMBITION)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01178073
First received: July 15, 2010
Last updated: May 22, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.


Condition Intervention Phase
Hypertension, Pulmonary
Drug: ambrisentan
Drug: tadalafil
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Time to Clinical Failure [ Time Frame: The study will be terminated when it is projected that approximately 105 events have occurred. Based on current assumptions, the median treatment duration is anticipated to be 2.25 years with the total study duration estimated at 3.5 years. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in 6 minute Walk Distance test [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Percentage of subjects with unsatisfactory clinical response [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline in N-terminal pro-B-type natriuretic peptide (NT-Pro BNP) [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline in World Health Organisation (WHO) Functional Class [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline in Borg Dyspnea Index [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Enrollment: 611
Study Start Date: October 2010
Estimated Study Completion Date: August 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Combination ambrisentan + tadalafil
ambrisentan + tadalafil
Drug: ambrisentan
ambrisentan (target dose: 10mg)
Drug: tadalafil
tadalafil (target dose: 40mg)
Active Comparator: Monotherapy ambrisentan
ambrisentan
Drug: ambrisentan
ambrisentan (target dose: 10mg)
Active Comparator: Monotherapy tadalafil
tadalafil
Drug: tadalafil
tadalafil (target dose: 40mg)

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have a diagnosis of Pulmonary Arterial Hypertension (PAH) due to the following:

    a. idiopathic or heritable PAH b. PAH associated with: i. connective tissue disease (e.g., limited scleroderma, diffuse scleroderma, mixed connective tissue disease, systemic lupus erythematosus, or overlap syndrome) ii. drugs or toxins iii. Human Immunodeficiency Virus (HIV) infection iv. congenital heart defects repaired greater than 1 year prior to screening (i.e., atrial septal defects, ventricular septal defects, and patent ductus arteriosus) NB: subjects with portopulmonary hypertension and pulmonary veno-occlusive disease are NOT eligible for the study

  • Subject must have a current diagnosis of being in World Health Organisation (WHO) Functional Class II or III.
  • Subject must meet all of the following haemodynamic criteria by means of a right heart catheterization prior to screening:

    i. mPAP of ≥25 mmHg ii. PVR ≥ 300 dynes/sec/cm5 iii. PCWP or LVEDP of ≤12 mmHg if PVR ≥300 to <500 dyne/sec/cm5 , or PCWP/LVEDP ≤ 15 mmHg if PVR ≥500 dynes/sec/cm5

  • Subject must walk a distance of ≥125m and ≤500m at the screening visit

Exclusion Criteria:

  • Subject received previous PAH therapy (phosphodiesterase type 5 inhibitor (PDE5i), endothelin receptor antagonist (ERA), chronic prostanoid*) within 4 weeks prior to the screening visit (*Chronic prostanoid use is considered >7 days of treatment)
  • Subject received ERA treatment (e.g., bosentan or sitaxentan) or PDE5i treatment (e.g. Sildenafil) at any time AND discontinued due to tolerance issues other than those associated with liver function abnormalities
  • Subjects who have previously discontinued ambrisentan or tadalafil in either another clinical study or commercial product (Volibris/Letairis or Adcirca) for safety or tolerability reasons.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01178073

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35294
GSK Investigational Site
Mobile, Alabama, United States, 36617
United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85012
GSK Investigational Site
Tucson, Arizona, United States, 85724
United States, California
GSK Investigational Site
La Jolla, California, United States, 92093
GSK Investigational Site
Los Angeles, California, United States, 90073
GSK Investigational Site
Sacramento, California, United States, 95817
GSK Investigational Site
Torrance, California, United States, 90502
United States, Colorado
GSK Investigational Site
Aurora, Colorado, United States, 80045
United States, Florida
GSK Investigational Site
Gainesville, Florida, United States, 32610
GSK Investigational Site
Jacksonville, Florida, United States, 32209
GSK Investigational Site
Kissimmee, Florida, United States, 34741
GSK Investigational Site
Orlando, Florida, United States, 32803
GSK Investigational Site
Weston, Florida, United States, 33331
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30322
GSK Investigational Site
Decatur, Georgia, United States, 30030
United States, Illinois
GSK Investigational Site
Oakbrook Terrace, Illinois, United States, 60181
United States, Indiana
GSK Investigational Site
Carmel, Indiana, United States, 46032
United States, Iowa
GSK Investigational Site
Iowa City, Iowa, United States, 52242
United States, Kansas
GSK Investigational Site
Kansas City, Kansas, United States, 66160
United States, Louisiana
GSK Investigational Site
New Orleans, Louisiana, United States, 70112
United States, Maine
GSK Investigational Site
Portland, Maine, United States, 04102
United States, Maryland
GSK Investigational Site
Baltimore, Maryland, United States, 21201
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02118
GSK Investigational Site
Boston, Massachusetts, United States, 02115
GSK Investigational Site
Boston, Massachusetts, United States, 02111
GSK Investigational Site
Springfield, Massachusetts, United States, 01199
United States, Michigan
GSK Investigational Site
Ann Arbor, Michigan, United States, 48109
GSK Investigational Site
Detroit, Michigan, United States, 48201
GSK Investigational Site
Troy, Michigan, United States, 48085
United States, Missouri
GSK Investigational Site
St. Louis, Missouri, United States, 63110
United States, Nebraska
GSK Investigational Site
Omaha, Nebraska, United States, 68131
United States, New Jersey
GSK Investigational Site
Morristown, New Jersey, United States, 07962
GSK Investigational Site
Newark, New Jersey, United States, 07112
United States, New York
GSK Investigational Site
New Hyde Park, New York, United States, 11040
GSK Investigational Site
New York, New York, United States, 10032
GSK Investigational Site
New York, New York, United States, 10003
GSK Investigational Site
New York, New York, United States, 10021
GSK Investigational Site
New York, New York, United States, 10019
GSK Investigational Site
Rochester, New York, United States, 14623
United States, North Carolina
GSK Investigational Site
Asheville, North Carolina, United States, 28803
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
GSK Investigational Site
Cincinnati, Ohio, United States, 45267
GSK Investigational Site
Cincinnati, Ohio, United States, 45219
GSK Investigational Site
Cleveland, Ohio, United States, 44195
GSK Investigational Site
Columbus, Ohio, United States, 43221
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97220
United States, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19140
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15212
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
GSK Investigational Site
Providence, Rhode Island, United States, 02903
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37232
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75390
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
Temple, Texas, United States, 76508
United States, Utah
GSK Investigational Site
Murray, Utah, United States, 84157
United States, Virginia
GSK Investigational Site
Charlottesville, Virginia, United States, 22908
GSK Investigational Site
Norfolk, Virginia, United States, 23507
GSK Investigational Site
Richmond, Virginia, United States, 23298
United States, Wisconsin
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53215
Australia, New South Wales
GSK Investigational Site
Camperdown, New South Wales, Australia, 2050
GSK Investigational Site
Darlinghurst, New South Wales, Australia, 2010
Australia, Queensland
GSK Investigational Site
Chermside, Queensland, Australia, 4032
Australia, Tasmania
GSK Investigational Site
Hobart, Tasmania, Australia, 7000
Australia, Victoria
GSK Investigational Site
Melbourne, Victoria, Australia, 3004
Australia, Western Australia
GSK Investigational Site
Perth, Western Australia, Australia, 6000
Austria
GSK Investigational Site
Innsbruck, Austria, A-6020
GSK Investigational Site
Vienna, Austria, 1090
Belgium
GSK Investigational Site
Brussels, Belgium, 1070
GSK Investigational Site
Leuven, Belgium, 3000
Canada, Alberta
GSK Investigational Site
Calgary, Alberta, Canada, T1Y 6J4
Canada, British Columbia
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R3A 1R8
Canada, Ontario
GSK Investigational Site
Toronto, Ontario, Canada, M5G 2N2
Canada, Quebec
GSK Investigational Site
Quebec City, Quebec, Canada, G1V 4G5
France
GSK Investigational Site
Brest, France, 29200
GSK Investigational Site
Bron, France, 69677
GSK Investigational Site
La Tronche, France, 38700
GSK Investigational Site
Le Kremlin-Bicêtre cedex, France, 94275
GSK Investigational Site
Lille, France, 59037
GSK Investigational Site
Marseille cedex 20, France, 13915
GSK Investigational Site
Montpellier cedex 5, France, 34295
GSK Investigational Site
Pessac cedex, France, 33604
GSK Investigational Site
Saint Pierre cedex, France, 97448
GSK Investigational Site
Toulouse cedex 9, France, 31059
GSK Investigational Site
Vandoeuvre-les-Nancy, France, 54511
Germany
GSK Investigational Site
Freiburg, Baden-Wuerttemberg, Germany, 79106
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69126
GSK Investigational Site
Loewenstein, Baden-Wuerttemberg, Germany, 74245
GSK Investigational Site
Muenchen, Bayern, Germany, 81377
GSK Investigational Site
Regensburg, Bayern, Germany, 93053
GSK Investigational Site
Wuerzburg, Bayern, Germany, 97076
GSK Investigational Site
Giessen, Hessen, Germany, 35392
GSK Investigational Site
Greifswald, Mecklenburg-Vorpommern, Germany, 17487
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53127
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50937
GSK Investigational Site
Homburg, Saarland, Germany, 66421
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
GSK Investigational Site
Leipzig, Sachsen, Germany, 04103
GSK Investigational Site
Berlin, Germany, 12559
GSK Investigational Site
Hamburg, Germany, 20246
Greece
GSK Investigational Site
Alexandroupolis, Greece, 68100
GSK Investigational Site
Athens, Greece, 124 62
GSK Investigational Site
Athens, Greece, 176 74
GSK Investigational Site
Thessaloniki, Greece, 54636
Italy
GSK Investigational Site
Bologna, Emilia-Romagna, Italy, 40138
GSK Investigational Site
Roma, Lazio, Italy, 00161
GSK Investigational Site
Cagliari, Sardegna, Italy, 09134
GSK Investigational Site
Catania, Sicilia, Italy, 95100
GSK Investigational Site
Pisa, Toscana, Italy, 56124
Japan
GSK Investigational Site
Fukuoka, Japan, 812-8582
GSK Investigational Site
Hokkaido, Japan, 060-8648
GSK Investigational Site
Shizuoka, Japan, 431-3192
GSK Investigational Site
Tokyo, Japan, 113-8655
Netherlands
GSK Investigational Site
Amsterdam, Netherlands, 1081 HV
GSK Investigational Site
Maastricht, Netherlands, 6229 HX
GSK Investigational Site
Rotterdam, Netherlands, 3015 CE
Spain
GSK Investigational Site
Barcelona, Spain, 08035
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Córdoba, Spain, 14004
GSK Investigational Site
L'Hospitalet de Llobregat, Spain, 08907
GSK Investigational Site
Madrid, Spain, 28034
GSK Investigational Site
Madrid, Spain, 28041
GSK Investigational Site
Majadahonda (Madrid), Spain, 28222
GSK Investigational Site
Malaga, Spain, 29010
GSK Investigational Site
Palma de Mallorca, Spain, 07010
GSK Investigational Site
Santander, Spain, 39008
GSK Investigational Site
Santiago de Compostela, Spain, 15706
GSK Investigational Site
Sevilla, Spain, 41013
GSK Investigational Site
Toledo, Spain, 45004
GSK Investigational Site
Valencia, Spain, 46026
Sweden
GSK Investigational Site
Göteborg, Sweden, SE-413 45
GSK Investigational Site
Linköping, Sweden, SE-581 85
GSK Investigational Site
Lund, Sweden, SE-221 85
GSK Investigational Site
Umeå, Sweden, SE-901 85
GSK Investigational Site
Uppsala, Sweden, SE-751 85
United Kingdom
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom, CB3 8RE
GSK Investigational Site
Clydebank, United Kingdom, G81 4DY
GSK Investigational Site
London, United Kingdom, SW3 6NP
GSK Investigational Site
London, United Kingdom, NW3 2QH
GSK Investigational Site
Sheffield, United Kingdom, S10 2JF
Sponsors and Collaborators
GlaxoSmithKline
Gilead Sciences
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01178073     History of Changes
Other Study ID Numbers: 112565
Study First Received: July 15, 2010
Last Updated: May 22, 2014
Health Authority: Spain: Agencia Española del Medicamento y Productos Sanitarios
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Austria: Agency for Health and Food Safety
Belgium: Agence Fédérale des Médicaments et des Produits de la Santé
Italy: Comitato Etico Indipendente
Canada: Health Canada
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte
France: Agence Française de Sécurité Sanitaire des Produits de Santé
Japan: Pharmaceuticals and Medical Devices Agency
Netherlands: De Centrale Commissie Mensgebonden Onderzoek
United States: Food and Drug Administration
Sweden: Läkemedelsverket
Australia: Therapeutic Goods Administration
Greece: National Drug Organisation

Keywords provided by GlaxoSmithKline:
Pulmonary Arterial Hypertension
Ambrisentan
Sponsor Rest of World: GSK
Tadalafil
PAH
Sponsor US: Gilead

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Tadalafil
Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents

ClinicalTrials.gov processed this record on September 18, 2014